ADXN Addex Therapeutics Ltd. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1574232 · Reporting currency CHF · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CHF | FY2024*2024-12-31 | FY2023*2023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 404,102 | 1.61M |
| R&D expense | 854,305 | 1.19M |
| SG&A expense | 2.31M | 2.67M |
| Operating income | -2.76M | -2.24M |
| Interest expense | 1,609 | 1,644 |
| Pretax income | -4.91M | -2.50M |
| Income tax | 0 | 0 |
| Net income | 7.06M | -10.56M |
| EPS (basic) | 0.07 | -0.14 |
| EPS (diluted) | 0.07 | -0.14 |
| Balance sheet | ||
| Cash & equivalents | 3.34M | 3.87M |
| Receivables | 15,513 | 110,361 |
| Current assets | 3.54M | 4.23M |
| PP&E, netmay include right-of-use assets (IFRS) | 1,131 | 22,604 |
| Total assets | 10.68M | 4.64M |
| Current liabilities | 802,093 | 2.89M |
| Short-term debt | 0 | 0 |
| Long-term debt | 0 | 0 |
| Total debt | 0 | 0 |
| Total liabilities | 1.00M | 3.50M |
| Shareholders' equity | 9.68M | 1.15M |
| Net debt | -3.34M | -3.87M |
| Shares outstanding | 128.29M | 125.20M |
| Cash flow statement | ||
| Operating cash flow | -5.37M | -7.99M |
| Capital expenditure | 1,273 | 6,842 |
| Free cash flow | -5.37M | -8.00M |
| Investing cash flow | 4.65M | -6,842 |
| Financing cash flow | 104,918 | 5.26M |
| Stock-based compensation | 502,964 | 1.79M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.